Clindamycin Phosphate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 19 USDMF, 12 CEP/COS, 6 JDMF, 1 EU WC, 1 KDMF, 13 NDC API, 18 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

17 Drugs in Development

17 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

168 FDF Dossiers, 133 FDA Orange Book, 10 Europe, 15 Canada, 1 South Africa, 9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;INTRAVENOUS - EQ 300MG BASE/50ML (EQ 6MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 600MG BASE/50ML (EQ 12MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 900MG BASE/50ML (EQ 18MG BASE/ML), INJECTABLE;INJECTION - EQ 150MG BASE/ML, SOLUTION;TOPICAL - EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, LOTION;TOPICAL - EQ 1% BASE, GEL;TOPICAL - EQ 1% BASE, GEL;TOPICAL - 5%;1.2%, GEL;TOPICAL - 5%;EQ 1% BASE, SUPPOSITORY;VAGINAL - 100MG, GEL;TOPICAL - EQ 1% BASE, CREAM;VAGINAL - EQ 2% BASE, AEROSOL, FOAM;TOPICAL - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, GEL;TOPICAL - 1.2%;0.025%

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 3 SPI Pharma, 3 DKSH, 1 Jai Radhe Sales, 1 Pharm-RX Chemical, 2 Gangwal Healthcare, 10 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 8 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 13 BASF, 1 BioSpectra, 1 Clariant, 6 Corel Pharma Chem, 2 Finar, 7 Gangwal Chemicals, 8 Kerry, 5 Lubrizol Life Science Health, 4 Microlex e.U, 1 Nanjing Bold Chemical, 2 Pluviaendo, 16 Roquette, 10 Seppic, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries, 1 Valens Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

36 Topical, 24 Solubilizers, 22 Parenteral, 21 Thickeners and Stabilizers, 16 Film Formers & Plasticizers, 14 Emulsifying Agents, 12 Fillers, Diluents & Binders, 9 Co-Processed Excipients, 9 Coating Systems & Additives, 8 Direct Compression, 8 Surfactant & Foaming Agents, 8 Controlled & Modified Release, 6 Lubricants & Glidants, 5 Taste Masking, 4 Rheology Modifiers, 4 Granulation, 3 API Stability Enhancers, 2 Chewable & Orodispersible Aids, 1 Soft Gelatin

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 54 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 9 Finished Drug Prices

MARKET PLACE

31 APIs, 4 FDF Dossiers

PATENTS & EXCLUSIVITIES

23 US Patents, 3 US Exclusivities

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 2 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 208083 / DOSAGE - SOLUTION;INTRAVENOUS - EQ 900MG BASE/50ML (EQ 18MG BASE/ML)

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
CLINDAMYCIN PHOSPHATE(UNII: EH6D7113I8) (CLINDAMYCIN - UNII:3U02EL437C)	CLINDAMYCIN PHOSPHATE	300mg in 50 \| 600mg in 50 \| 900mg in 50

Inactive Ingredients

Ingredient Name	Baxter Healthcare Corporation
EDETATE DISODIUM(7FLD91C86K)
HYDROCHLORIC ACID(QTT17582CB)
SODIUM CHLORIDE(451W47IQ8X)
SODIUM HYDROXIDE(55X04QC32I)
WATER(059QF0KO0R)

Drug Product Composition: Clindamycin Phosphate